Revance Therapeutics (RVNC) Competitors $3.09 +0.02 (+0.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RVNC vs. DAWN, ARDX, SYRE, CALT, SPRY, ANIP, SNDX, INVA, ELVN, and RCKTShould you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), Innoviva (INVA), Enliven Therapeutics (ELVN), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry. Revance Therapeutics vs. Day One Biopharmaceuticals Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) ARS Pharmaceuticals ANI Pharmaceuticals Syndax Pharmaceuticals Innoviva Enliven Therapeutics Rocket Pharmaceuticals Day One Biopharmaceuticals (NASDAQ:DAWN) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership. Do insiders & institutionals have more ownership in DAWN or RVNC? 87.9% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are held by institutional investors. 8.4% of Day One Biopharmaceuticals shares are held by insiders. Comparatively, 5.1% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, DAWN or RVNC? Day One Biopharmaceuticals has a beta of -1.51, suggesting that its share price is 251% less volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Is DAWN or RVNC more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% Revance Therapeutics -74.67%N/A -37.22% Does the MarketBeat Community believe in DAWN or RVNC? Revance Therapeutics received 356 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. However, 66.18% of users gave Day One Biopharmaceuticals an outperform vote while only 61.50% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes4566.18% Underperform Votes2333.82% Revance TherapeuticsOutperform Votes40161.50% Underperform Votes25138.50% Which has higher valuation & earnings, DAWN or RVNC? Day One Biopharmaceuticals has higher earnings, but lower revenue than Revance Therapeutics. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$101.95M12.65-$188.92M-$1.03-12.42Revance Therapeutics$256.95M1.26-$323.99M-$1.93-1.60 Do analysts prefer DAWN or RVNC? Day One Biopharmaceuticals currently has a consensus price target of $35.71, indicating a potential upside of 179.24%. Revance Therapeutics has a consensus price target of $8.96, indicating a potential upside of 189.88%. Given Revance Therapeutics' higher possible upside, analysts clearly believe Revance Therapeutics is more favorable than Day One Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Revance Therapeutics 0 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.11 Does the media prefer DAWN or RVNC? In the previous week, Revance Therapeutics had 2 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 6 mentions for Revance Therapeutics and 4 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.79 beat Revance Therapeutics' score of 0.79 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revance Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDay One Biopharmaceuticals beats Revance Therapeutics on 11 of the 19 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVNC vs. The Competition Export to ExcelMetricRevance TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$322.57M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-1.6010.4289.5817.17Price / Sales1.26195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-1.795.094.774.78Net Income-$323.99M$151.83M$120.15M$225.60M7 Day Performance0.32%-2.13%-1.92%-1.23%1 Month Performance-19.53%-3.10%11.47%3.36%1 Year Performance-63.35%11.54%30.54%16.60% Revance Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVNCRevance Therapeutics3.7068 of 5 stars$3.09+0.7%$8.96+189.9%-59.2%$322.57M$256.95M-1.60597Analyst ForecastNews CoverageDAWNDay One Biopharmaceuticals1.6211 of 5 stars$12.74-0.1%$35.71+180.3%-7.7%$1.28B$101.95M-12.3860ARDXArdelyx3.6907 of 5 stars$5.39+3.3%$10.42+93.3%-18.9%$1.28B$251.85M-17.80267SYRESpyre Therapeutics1.77 of 5 stars$24.65+2.2%$51.50+108.9%+53.4%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.1441 of 5 stars$12.26+3.0%$24.00+95.8%+121.8%$1.19B$30,000.00-23.3390Insider TradeNews CoverageANIPANI Pharmaceuticals4.836 of 5 stars$56.07-0.9%$77.71+38.6%+1.9%$1.18B$555.46M-102.89642Insider TradeSNDXSyndax Pharmaceuticals3.9607 of 5 stars$13.73-1.4%$37.64+174.1%-33.6%$1.17B$16M-3.84110News CoverageINVAInnoviva1.9799 of 5 stars$18.54-0.2%N/A+11.7%$1.16B$310.46M26.93112ELVNEnliven Therapeutics2.7893 of 5 stars$23.55+1.7%$38.25+62.4%+84.3%$1.15BN/A-12.4350Positive NewsRCKTRocket Pharmaceuticals4.8494 of 5 stars$11.94-0.7%$51.00+327.1%-58.6%$1.09BN/A-4.37240Analyst Forecast Related Companies and Tools Related Companies DAWN Competitors ARDX Competitors SYRE Competitors CALT Competitors SPRY Competitors ANIP Competitors SNDX Competitors INVA Competitors ELVN Competitors RCKT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RVNC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
